Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy

Journal of Urology

Volumn 156, Issue 3, 1996, Pages 1064-1068

  Bettencourt, Marie Claude ^b   Bauer, John J ^b   Sesterhenn, Isabell A ^b   Mostofi, F K ^b   Mcleod, David G ^b   Moul, Judd W ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NONE

Author keywords

neoplasm metastasis; prostatectomy; prostatic neoplasms; tumor markers, biological

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

EID: 0029759731     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65703-3     Document Type: Article

References (30)

1. Boring, C. C., Squires, T. S., Tong, T. and Montgomery, S.: Cancer statistics, 1994. CA, 44: 7, 1994.
2. Lu-Yao, G. L., McLerran, D., Wasson, J. and Wennberg, J. E.: An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. J.A.M.A., 269: 2633, 1993.
3. Wasson, J. H., Cushman, C. C., Bruskewitz, R. C., Littenberg, B., Mulley, A. G., Jr. and Wennberg, J. E.: A structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team. Arch. Fam. Med., 2: 487, 1993.
4. Brown, D. C. and Gatter, K. C.: Monoclonal antibody Ki-67: its use in histopathology. Histopathology, 17: 489, 1990.
5. Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U. and Stein, H.: Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol., 133: 1710, 1984.
6. Cher, M. L., Chew, K., Rosenau, W. and Carroll, P. R.: Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate, 26: 87, 1995.
7. Gallee, M. P. W., Visser-de Jong, E., ten Kate, F. J. W., Schroeder, F. H. and van der Kwast, Th. H.: Monoclonal antibody Ki-67 defined growth fraction in benign prostatic hyperplasia and prostatic cancer. J. Urol., 142: 1342, 1989.
8. Raymond, W. A., Leong, A. S.-Y., Bolt, J. W., Milios, J. and Jose, J. S.: Growth fractions in human prostatic carcinoma determined by the Ki-67 immunostaining. J. Path., 156: 161, 1988.
9. Oomens, E. H. G. M., Van Steenbrugge, G. J., Van Der Kwast, Th. H. and Schröder, F. H.: Application of the monoclonal antibody Ki-67 on prostate biopsies to assess the proliferative cell fraction of human prostatic carcinoma. J. Urol., 145: 81, 1991.
10. McLoughlin, J., Foster, C. S., Price, P., Williams, G. and Abel, P. D.: Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma. Brit. J. Urol., 72: 92, 1993.
11. Sadi, M. V. and Barrack, E. R.: Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy. Cancer, 67: 3065, 1991.
12. Van Weerden, W. M., Moerings, E. P., van Kreuningen, A., de Jong, F. H., van Steenbrugge, G. J. and Schröder, F. H.: Ki-67 expression and BrdUrd incorporation as markers of proliferative activity in human prostate tumour models. Cell Prolif., 26: 67, 1993.
13. Cattoretti, G., Becker, M. H., Key, G., Duchrow, M., Schlüter, C., Galle, J. and Gerdes, J.: Monoclonal antibody against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J. Path., 168: 357, 1992.
14. Partin, A. W. and Oesterling, J. E.: The clinical usefulness of prostate specific antigen. Update 1994. J. Urol., 152: 1358, 1994.
15. Gleason, D. F.: Histologie grading and clinical staging of prostatic carcinoma. In: Urologic Pathology: The Prostate. Edited by M. Tannenbaum. Philadelphia: Lea & Febiger, chapt. 9, pp. 171-198, 1977.
16. Mostofi, D. F., Sesterhenn, I. A. and Sobin, L. H.: Histological Typing of Prostate Tumours. Geneva: World Health Organization, 1980.
17. Ohori, M., Wheeler, T. M. and Scardino, P. T.: The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer, 74: 104, 1994.
18. Bauer, J., Sesterhenn, L, Mostofi, F. K., McLeod, D., Srivastava, S. and Moul, J.: p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin. Cancer Res., 1: 1295, 1995.
19. Berges, R., Vukanovic, J., Epstein, J. L, CarMichel, M., Cisek, L., Johnson, D. E., Veltri, R. W., Walsh, P. and Isaacs, J. T.: Implication of cell kinetic changes during the progression of human prostate cancer. Clin. Cancer Res., 1: 473, 1995.
20. Meyer, J. S., Sufrin, G. and Martin, S. A.: Proliferative activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labeling. J. Urol., 128: 1353, 1982.
21. Nemoto, R., Hattori, K., Uchida, K, Shimazui, T., Nishijima, Y., Koiso, K. and Harada, M.: S-phase fraction of human prostate adenocarcinoma studies with in vivo bromodeoxyuridine labeling. Cancer, 66: 509, 1990.
22. Harper, M. E., Goddard, L., Wilson, D. W., Matanhelia, S. S., Conn, I. G., Peeling, W. B. and Griffiths, K.: Pathological and clinical associations of Ki-67 defined growth fractions in human prostatic carcinoma. Prostate, 21: 75, 1992.
23. Noordzij, M., van der Kwast, T. H., van Steenbrugge, G. J., van Weerden, W. M., Oomen, M. H. and Schroder, F. H.: Determination of Ki-67 defined growth fraction by monoclonal antibody MIB-1 in formalin-fixed, parrafin-embedded prostatic cancer tissues. Prostate, 27: 154, 1995.
24. Oesterling, J. E., Chan, D. W., Epstein, J. L, Kimball, A. W., Jr., Bruzek, D. J., Rock, R. C., Brendler, C. B. and Walsh, P. C.: Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urol., 139: 766, 1988.
25. Partin, A. W., Yoo, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I. and Walsh, P. C.: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol., 150: 110, 1993.
26. D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Schnall, M., Tomaszewski, J. E. and Wein, A.: A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J. Urol., 154: 131, 1995.
27. Partin, A. W., Piantadosi, S., Sanda, M. G., Epstein, J. I., Marshall, F. F., Mohler, J. J., Brendler, C. B., Walsh, P. C. and Simons, J. W.: Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology, 45: 831, 1995.
28. Partin, A. W., Pound, C. R., Clemens, J. Q., Epstein, J. I. and Walsh, P. C.: Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol. Clin. N. Amer., 20: 713, 1993.
29. Boring, C. C., Squires, T. S. and Heath, C. W., Jr.: Cancer statistics for African Americans. CA, 42: 7, 1992.
30. Moul, J. W., Sesterhenn, I. A., Connelly, R. R., Douglas, T., Srivastava, S., Mostofi, F. K. and McLeod, D. G.: Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. J.A.M.A., 274: 1277, 1995.